CombiGene AB announced that the GMP production of CG01 has been made available for the concluding preclinical studies planned to enable First In Human study. This is the first large scale GMP production of CG01, and both the production itself and the subsequent testing were performed according to original plans. The data from the analyses will form a central part of future regulatory applications to support proceeding to clinical studies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.56 SEK | -3.78% | -4.56% | +32.34% |
13/03 | CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries | CI |
21/02 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
1st Jan change | Capi. | |
---|---|---|
+32.34% | 6.5M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- COMBI Stock
- News CombiGene AB
- Combigene AB Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study